Galactomannan and advances in fungal diagnostics

Current Opinion in Organ Transplantation

Volumn 10, Issue 4, 2005, Pages 307-311

  Zaas, Aimee K ^a   Alexander, Barbara D ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Fungal diagnostics; Galactomannan; Glucan; Peptide nucleic acid fluorescent in situ hybridization

Indexed keywords

ANTIGEN; GALACTOMANNAN; GLUCAN;

ASPERGILLOSIS; ASPERGILLUS; CANDIDIASIS; DIAGNOSTIC PROCEDURE; EARLY DIAGNOSIS; ENZYME IMMUNOASSAY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNE DEFICIENCY; LABORATORY TEST; LEUKEMIA; MORBIDITY; MORTALITY; MYCOSIS; PHYSICIAN; REVIEW; SENSITIVITY AND SPECIFICITY;

EID: 28044464676     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/01.mot.0000187102.18780.b0     Document Type: Review

References (32)

1. Platelia Aspergillus EIA [package insert]. Redmond, WA: Bio-Rad; 2003.
2. Maertens J, Verhaegen J, Demuynck H, et al. Autopsy-controlled prospective evaluation of serial screening for circulating galactomannan by a sandwich enzyme-linked immunosorbent assay for hematological patients at risk for invasive Aspergillosis. J Clin Microbiol 1999; 37:3223-3228.
3. Sulahian A, Boutboul F, Ribaud P, et al. Value of antigen detection using an enzyme immunoassay in the diagnosis and prediction of invasive aspergillosis in two adult and pediatric hematology units during a 4-year prospective study. Cancer 2001; 91:311-318.
4. Maertens J, Verhaegen J, Demuynck H, et al. Autopsy-controlled prospective evaluation of serial screening for circulating galactomannan by a sandwich enzyme-linked immunosorbent assay for hematological patients at risk for invasive aspergillosis. J Clin Microbiol 1999; 37:3223-3228.
5. Maertens J, Van Eldere J, Verhaegen J, et al. Use of circulating galactomannan screening for early diagnosis of invasive aspergillosis in allogeneic stem cell transplant recipients. J Infect Dis 2002; 186:1297-1306.
6. Marr KA, Balajee SA, McLaughlin L, et al. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. J Infect Dis 2004; 190:641-649. Highlights the need to interpret galactomannan testing in the context of antifungal use. Clinicians need to be aware of galactomannan kinetics and how this assay performs in nonclinical trial settings.
7. Marr KA, Laverdiere M, Gugel A, Leisenring W. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin Infect Dis 2005; 40:1762-1769.
8. Maertens J, Theunissen K, Verbeken E, et al. Prospective clinical evaluation of lower cut-offs for galactomannan detection in adult neutropenic cancer patients and haematological stem cell transplant recipients. Br J Haematol 2004; 126:852-860. Evaluates the appropriate cutoff values for determining a 'positive' galactomannan test.
9. Musher B, Fredricks D, Leisenring W, et al. Aspergillus galactomannan enzyme immunoassay and quantitative PCR for diagnosis of invasive aspergillosis with bronchoalveolar lavage fluid. J Clin Microbiol 2004; 42:5517-5522. A burgeoning field is the use of fungal diagnostics on nonserum specimens. It is expected that use of the galactomannan antigenemia in bronchoalveolar lavage fluid will be a clinically important diagnostic tool.
10. Becker MJ, Lugtenburg EJ, Cornelissen JJ, et al. Galactomannan detection in computerized tomography-based broncho-alveolar lavage fluid and serum in haematological patients at risk for invasive pulmonary aspergillosis. Br J Haematol 2003; 121:448-457.
11. Adam O, Auperin A, Wilquin F, et al. Treatment with piperacillin- tazobactam and false-positive Aspergillus galactomannan antigen test results for patients with hematological malignancies. Clin Infect Dis 2004; 38:917-920.
12. Sulahian A, Touratier S, Ribaud P. False positive test for aspergillus antigenemia related to concomitant administration of piperacillin and tazobactam. N Engl J Med 2003; 349:2366-2367.
13. Viscoli C, Machetti M, Cappellano P, et al. False-positive galactomannan Platelia Aspergillus test results for patients receiving piperacillin- tazobactam. Clin Infect Dis 2004; 38:913-916.
14. Maertens J, Theunissen K, Verhoef G, Van Eldere J. False-positive Aspergillus galactomannan antigen test results. Clin Infect Dis 2004; 39:289-290. Summarizes expert opinion on the role of β-lactam antibiotics and false-positive galactomannan results.
15. Mattel D, Rapezzi D, Mordini N, et al. False-positive Aspergillus galactomannan enzyme-linked immunosorbent assay results in vivo during amoxicillin-clavulanic acid treatment. J Clin Microbiol 2004; 42:5362-5363.
16. Mennink-Kersten MA, Donnelly JP, Verweij PE. Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. Lancet Infect Dis 2004; 4:349-357.
17. Mennink-Kersten MA, Klont RR, Warris A, et al. Bifidobacterium lipoteichoic acid and false ELISA reactivity in Aspergillus antigen detection. Lancet 2004; 363:325-327.
18. Husain S, Kwak EJ, Obman A, et al. Prospective assessment of Platelia Aspergillus galactomannan antigen for the diagnosis of invasive aspergillosis in lung transplant recipients. Am J Transplant 2004; 4:796-802.
19. Kwak EJ, Husain S, Obman A, et al. Efficacy of galactomannan antigen in the Platelia Aspergillus enzyme immunoassay for diagnosis of invasive aspergillosis in liver transplant recipients. J Clin Microbiol 2004; 42:435-438.
20. Ostrosky-Zeichner L, Alexander BD, Kett DH, et al. Multicenter clinical evaluation of the (1→3) B-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 2005; 41:654-659.
21. Odabasi Z, Mattiuzzi G, Estey E, et al. Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 2004; 39:199-205. Largest trial to date evaluating performance of the 1→3 β-D-glucan assay for the diagnosis of fungal infections, including candidiasis and aspergillosis.
22. Pazos C, Ponton J, Del Palacio A. Contribution of (1→3)-beta-D- glucan chromogenic assay to diagnosis and therapeutic monitoring of invasive aspergillosis in neutropenic adult patients: a comparison with serial screening for circulating galactomannan. J Clin Microbiol 2005; 43:299-305.
23. Mori T, Matsumura M. Clinical evaluation of diagnostic methods using plasma and/or serum for three mycoses: aspergillosis, candidosis, and pneumocystosis. Nippon Ishinkin Gakkai Zasshi 1999; 40:223-230.
24. Odabasi Z, Mattiuzzi G, Estey E, et al. Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 2004; 39:199-205.
25. Yoshida M, Obayashi T, Iwama A, et al. Detection of plasma (1→3)-beta-D-glucan in patients with Fusarium, Trichosporon, Saccharomyces and Acremonium fungaemias. J Med Vet Mycol 1997; 35:371-374.
26. Jojima H. Early diagnosis and treatment of pulmonary opportunistic infection by using polymerase chain reaction and beta-glucan in patients with hematological neoplasms. Kurume Med J 2001; 48:117-127.
27. Miyazaki T, Kohno S, Mitsutake K, et al. Plasma (1→3)-beta-D-glucan and fungal antigenemia in patients with candidemia, aspergillosis, and cryptococcosis. J Clin Microbiol 1995; 33:3115-3118.
28. Kato A, Takita T, Furuhashi M, et al. Elevation of blood (1→3)-beta-D-glucan concentrations in hemodialysis patients. Nephron 2001; 89:15-19.
29. Nakao A, Yasui M, Kawagoe T, et al. False-positive endotoxemia derives from gauze glucan after hepatectomy for hepatocellular carcinoma with cirrhosis. Hepatogastroenterology 1997; 44:1413-1418.
30. Ikemura K, Tanaka H, Yoshioka T, Sugimoto T. Interference in endotoxin and fungal polysaccharide assays from blood products and antimicrobial agents [in Japanese]. Rinsho Byori 1990; 38:87-92.
31. Kawazu M, Kanda Y, Nannya Y, et al. Prospective comparison of the diagnostic potential of real-time PCR, double-sandwich enzyme-linked immunosorbent assay for galactomannan, and a (1→3)-beta-D-glucan test in weekly screening for invasive aspergillosis in patients with hematological disorders. J Clin Microbiol 2004; 42:2733-2741.
32. Wilson DA, Joyce MJ, Hall LS, et al. Multicenter evaluation of a Candida albicans peptide nucleic acid fluorescent in situ hybridization probe for characterization of yeast isolates from blood cultures. J Clin Microbiol 2005; 43:2909-2912. Shows that PNA FISH may help clinicians determine albicans vs. non-albicans Candida in a timely manner. This could facilitate earlier use of azoles, with significant cost saving.